PMN: Interim trial data reveal zero ARIA cases and promising biomarker shifts for a novel Alzheimer's antibody
A novel antibody therapy for Alzheimer's showed strong interim safety and promising biomarker engagement in a 144-patient phase Ib trial, with zero cases of ARIA and a 15% decline in p-tau217. Well-funded and FDA Fast Tracked, the program aims for phase III and broader neurodegenerative indications…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.